April 26 (Reuters) - Prometic Life Sciences Inc PLI.TO
* Prometic's PBI-4050: efficacy further evidenced in type 2
diabetic and metabolic syndrome clinical trial
* New results from additional patients increase statistical
and clinical evidence of efficacy
* Reduction of glycated hemoglobin (hba1c) reaches -0.9%
(p=0.0004) in patients with hba1c 8% at baseline
Source text for Eikon: ID:nCNWSWq1la
Further company coverage: PLI.TO
(Bengaluru Newsroom: +1-646-223-8780)